Literature DB >> 30879436

Reduced Intracerebral Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas.

Hannah Irvine1,2, Shailesh Male1,2, Jetter Robertson1,2, Caitlin Bell1,2, Oladi Bentho1,2, Christopher Streib1,2.   

Abstract

Background and Purpose- Sulfonylurea medications have been linked to reduced brain edema and improved outcome following ischemic stroke, but their effects on primary intracerebral hemorrhage (pICH) have not been thoroughly explored. Increasing ICH volume and perihematomal edema (PHE) volume are predictors of poor outcome in pICH. We investigated whether preexisting sulfonylurea use influenced ICH volume, PHE volume, and discharge disposition in patients with type 2 diabetes mellitus presenting with pICH. Methods- We performed a retrospective chart review of all diabetic patients presenting with pICH to 2 tertiary academic centers from 2006 to 2016. All patients with diabetes mellitus, pICH, admission computed tomography scan, and sulfonylurea use on admission were included in our study. For each case, 2-matched controls (admission date, age, hematoma location [deep versus lobar], use of antiplatelet, or anticoagulant) with diabetes mellitus and pICH were consecutively selected. ICH and PHE volumes were measured via region of interest analysis on admission computed tomography. To mitigate the influence of ICH volume on PHE, the PHE/ICH surface area ratio was calculated. Hospital discharge disposition was determined via chart abstraction. We used the Wilcoxon rank-sum test and Fisher exact test to compare cases and controls. Results- Of 317 patients screened, 21 sulfonylurea cases and 42-matched controls met criteria for study inclusion. Sulfonylurea cases had significantly lower admission ICH volumes (median, 4 mL; interquartile range [IQR], 2-30 versus median, 25 mL; IQR, 6-60; P=0.011), PHE volumes (median, 4 mL; IQR, 0.9-24 versus median, 17; IQR, 6-37; P=0.0095), and PHE/ICH surface area ratios (median, 0.28; IQR, 0.1-0.4 versus median, 0.43; IQR, 0.3-0.6; P=0.013) as compared with controls. Sulfonylureas were associated with improved discharge disposition ( P=0.0062). Conclusions- In patients with diabetes mellitus and pICH, sulfonylurea use predicted lower ICH and PHE volumes, lower relative PHE, and improved discharge disposition. Given the paucity of treatment options for pICH, further study of sulfonylureas is warranted.

Entities:  

Keywords:  cerebral infarction; edema; endothelial cells; hematoma; inflammation

Year:  2019        PMID: 30879436     DOI: 10.1161/STROKEAHA.118.022301

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

Review 1.  Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?

Authors:  Francisco J Pasquel; Maya Fayfman; Guillermo E Umpierrez
Journal:  Curr Diab Rep       Date:  2019-07-29       Impact factor: 4.810

2.  Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): Study Protocol for a Multicenter Randomized, Controlled, Assessor-Blinded Trial.

Authors:  Jingjing Zhao; Fang Yang; Changgeng Song; Li Li; Xiai Yang; Xiaofeng Wang; Liping Yu; Jun Guo; Kangjun Wang; Feng Fu; Wen Jiang
Journal:  Front Neurol       Date:  2021-04-27       Impact factor: 4.003

Review 3.  Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage.

Authors:  Mais N Al-Kawaz; Daniel F Hanley; Wendy Ziai
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  LncRNA MALAT1 induced by hyperglycemia promotes microvascular endothelial cell apoptosis through activation of the miR-7641/TPR axis to exacerbate neurologic damage caused by cerebral small vessel disease.

Authors:  Fei Che; Yunfeng Han; Jinxia Fu; Nannan Wang; Yuehui Jia; Kun Wang; Jie Ge
Journal:  Ann Transl Med       Date:  2021-12

5.  Reduction of lactoferrin aggravates neuronal ferroptosis after intracerebral hemorrhagic stroke in hyperglycemic mice.

Authors:  Zhongnan Xiao; Danmin Shen; Ting Lan; Chao Wei; Weihua Wu; Qingyu Sun; Zhaoli Luo; Wen Chen; Yurui Zhang; Liye Hu; Chenguang Zhang; Yamei Wang; Yabin Lu; Peipei Wang; Fei Yang; Qian Li
Journal:  Redox Biol       Date:  2022-02-02       Impact factor: 11.799

Review 6.  Molecular, Pathological, Clinical, and Therapeutic Aspects of Perihematomal Edema in Different Stages of Intracerebral Hemorrhage.

Authors:  Chao Jiang; Hengtao Guo; Zhiying Zhang; Yali Wang; Simon Liu; Jonathan Lai; Tom J Wang; Shize Li; Jing Zhang; Li Zhu; Peiji Fu; Jiewen Zhang; Jian Wang
Journal:  Oxid Med Cell Longev       Date:  2022-09-17       Impact factor: 7.310

7.  Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial.

Authors:  Jingjing Zhao; Changgeng Song; Deshuai Li; Xiai Yang; Liping Yu; Kangjun Wang; Jun Wu; Xiaofeng Wang; Dongsong Li; Bo Zhang; Binyong Li; Jun Guo; Weikui Feng; Feng Fu; Xinrong Gu; Jian Qian; Jialong Li; Xiangjun Yuan; Qiuwu Liu; Jiang Chen; Xiaocheng Wang; Yi Liu; Dong Wei; Ling Wang; Lei Shang; Fang Yang; Wen Jiang
Journal:  EClinicalMedicine       Date:  2022-09-23

8.  In vivo therapeutic exploring for Mori folium extract against type 2 diabetes mellitus in rats.

Authors:  Kaibo Lyu; Wei Yue; Junhua Ran; Yunjuan Liu; Xueliang Zhu
Journal:  Biosci Rep       Date:  2021-12-22       Impact factor: 3.840

9.  Disability-Adjusted Life-Years Associated With Intracerebral Hemorrhage and Secondary Injury.

Authors:  David Haupenthal; Joji B Kuramatsu; Bastian Volbers; Jochen A Sembill; Anne Mrochen; Stefanie Balk; Philip Hoelter; Hannes Lücking; Tobias Engelhorn; Arnd Dörfler; Stefan Schwab; Hagen B Huttner; Maximilian I Sprügel
Journal:  JAMA Netw Open       Date:  2021-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.